Literature DB >> 8472857

C-myc gene chromatin of estrogen receptor positive and negative breast cancer cells.

T L Miller1, N J Huzel, J R Davie, L C Murphy.   

Abstract

Expression of the c-myc protooncogene is estrogen regulated in estrogen receptor (ER) positive, hormone-dependent human breast cancer cells, but it is constitutively active in ER negative, hormone-independent breast cancer cells. To determine whether these differences are reflected in c-myc chromatin, DNase I hypersensitive sites (DHS) were mapped. Six DHS were detected in all cell lines studied, with DHS 3(2) being more prominent than DHS 3(1). The accessibility of DHS 2 was markedly greater in ER negative cells than in ER positive cells, and this relative accessibility remained unchanged when cells were grown in estrogen free medium. DHS 2, 3(1) and 3(2) map near the P0, P1 and P2 promoters, respectively. An analysis of promoter usage demonstrated that P2 was the preferred promoter. Thus, the differences in the accessibility of DHS 2 in c-myc chromatin of ER positive and negative cells likely reflects alterations in DNA-protein interactions in this region.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8472857     DOI: 10.1016/0303-7207(93)90258-l

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  4 in total

1.  Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor.

Authors:  Chunyu Wang; Julie Ann Mayer; Abhijit Mazumdar; Kirsten Fertuck; Heetae Kim; Myles Brown; Powel H Brown
Journal:  Mol Endocrinol       Date:  2011-08-11

2.  Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.

Authors:  Amylou C Dueck; Monica M Reinholz; Xochiquetzal J Geiger; Kathleen Tenner; Karla Ballman; Robert B Jenkins; Darren Riehle; Beiyun Chen; Ann E McCullough; Nancy E Davidson; Silvana Martino; George W Sledge; Peter A Kaufman; Leila A Kutteh; Julie Gralow; Lyndsay N Harris; James N Ingle; Wilma L Lingle; Edith A Perez
Journal:  Clin Cancer Res       Date:  2013-08-21       Impact factor: 12.531

3.  Cohesin is required for activation of MYC by estradiol.

Authors:  Miranda V McEwan; Michael R Eccles; Julia A Horsfield
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

4.  Small molecule inhibitors of IRES-mediated translation.

Authors:  Christos Vaklavas; Zheng Meng; Hyoungsoo Choi; William E Grizzle; Kurt R Zinn; Scott W Blume
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.